

## DAFTAR PUSTAKA

- Advani, R. *et al.* 2018. 'CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.', *N. Engl. J. Med.*, 379(18), pp. 1711–1721.
- Ali, K. *et al.* 2010. 'Yogyakarta Pediatric Cancer Registry: an international collaborative project of University Gadjah Mada, University of Saskatchewan, and the Saskatchewan Cancer Agency.', *Asian Pac. J. Cancer Prev.*, 11(1), pp. 131–136.
- Alkatan, H.M., ALBalawi, H. & Maktabi, A.M.Y. 2018. 'The value of "en toto" globe submission in the assessment of high-risk retinoblastoma cases and staging.', *Int. Ophthalmol.*, 38(1), pp. 35–41.
- Alsharif, H., Helmi, H. & Maktabi, A. 2019. 'Histopathological Characteristics and Classification for Prognostic Indicators', in Alkatan, H.M. (ed.) *Retinoblastoma*. Rijeka: IntechOpen.
- Andrejeva, G. *et al.* 2021. 'Novel SIRP $\alpha$  Antibodies That Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells.', *J. Immunol.*, 206(4), pp. 712–721.
- Andreoli, M.T. *et al.* 2017. 'Epidemiological trends in 1452 cases of retinoblastoma from the Surveillance, Epidemiology, and End Results (SEER) registry.', *Can. J. Ophthalmol.*, 52(6), pp. 592–598.
- Areán, C. *et al.* 2010. 'Expression of vascular endothelial growth factor in retinoblastoma', *Arch. Ophthalmol.*, 128(2), pp. 223–229.
- Arrieta, O. *et al.* 2020. 'Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non-small cell lung cancer.', *Cancer Med.*, 9(7), pp. 2390–2402.
- Asina Miranda, G. & Simanjuntak, G.W.S. 2018. 'Clinical Findings and Demography of Retinoblastoma in a Tertiary Hospital in a Remote Area in a Developing Country', *Asian Pacific J. Cancer Care*, 3(2), p. 37.
- Barclay, A.N. 2009. 'Signal regulatory protein alpha (SIRP $\alpha$ )/CD47 interaction and function.', *Curr. Opin. Immunol.*, 21(1), pp. 47–52.
- Barclay, A.N. & Van den Berg, T.K. 2014. 'The interaction between signal regulatory protein alpha (SIRP $\alpha$ ) and CD47: structure, function, and therapeutic target.', *Annu. Rev. Immunol.*, 32, pp. 25–50.
- Brown, B.J., Adeleye, A.O. & Ibeh, J.N. 2015. 'A Prospective Study on the Causes of Delayed Diagnosis of Childhood Cancer in Ibadan, Nigeria.', *Pediatr. Hematol. Oncol.*, 32(6), pp. 365–373.
- Brown, E.J. & Frazier, W.A. 2001. 'Integrin-associated protein (CD47) and its ligands.', *Trends Cell Biol.*, 11(3), pp. 130–135.
- Buchholz, T.A. *et al.* 2002. 'Global gene expression changes during neoadjuvant chemotherapy for human breast cancer.', *Cancer J.*, 8(6), pp. 461–468.
- Chantada, G. *et al.* 1999. 'Late diagnosis of retinoblastoma in a developing country.', *Arch. Dis. Child.*, 80(2), pp. 171–174.
- Chao, M.P., Tang, C., *et al.* 2011. 'Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy.', *Blood*, 118(18), pp. 4890–4901.
- Chao, M.P., Alizadeh, A.A., *et al.* 2011. 'Therapeutic antibody targeting of CD47

- eliminates human acute lymphoblastic leukemia.’, *Cancer Res.*, 71(4), pp. 1374–1384.
- Chawla, B. *et al.* 2016. ‘Clinical presentation and survival of retinoblastoma in Indian children.’, *Br. J. Ophthalmol.*, 100(2), pp. 172–178.
- Chen, M. *et al.* 2017. ‘Outcome of intra-arterial chemotherapy for retinoblastoma and its influencing factors: a retrospective study.’, *Acta Ophthalmol.*, 95(6), pp. 613–618.
- Chintagumpala, M. *et al.* 2007. ‘Retinoblastoma: review of current management.’, *Oncologist*, 12(10), pp. 1237–1246.
- Cooper, D. *et al.* 1995. ‘Transendothelial migration of neutrophils involves integrin-associated protein (CD47).’, *Proc. Natl. Acad. Sci. U. S. A.*, 92(9), pp. 3978–3982.
- Dhar, S.U. *et al.* 2011. ‘Outcomes of integrating genetics in management of patients with retinoblastoma.’, *Arch. Ophthalmol. (Chicago, Ill. 1960)*, 129(11), pp. 1428–1434.
- Dimaras, H. *et al.* 2008. ‘Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma.’, *Hum. Mol. Genet.*, 17(10), pp. 1363–1372.
- Dimaras, H. *et al.* 2012. ‘Retinoblastoma.’, *Lancet (London, England)*, 379(9824), pp. 1436–1446.
- Dimaras, H. *et al.* 2015. ‘Retinoblastoma.’, *Nat. Rev. Dis. Prim.*, 1, p. 15021.
- Dizman, N. & Buchbinder, E.I. 2021. ‘Cancer Therapy Targeting CD47/SIRPα.’, *Cancers (Basel)*, 13(24).
- Eagle, R.C.J. 2009. ‘High-risk features and tumor differentiation in retinoblastoma: a retrospective histopathologic study.’, *Arch. Pathol. Lab. Med.*, 133(8), pp. 1203–1209.
- Eagle, R.C.J. 2013. ‘The pathology of ocular cancer.’, *Eye (Lond)*, 27(2), pp. 128–136.
- Emens, L.A. & Middleton, G. 2015. ‘The interplay of immunotherapy and chemotherapy: harnessing potential synergies.’, *Cancer Immunol. Res.*, 3(5), pp. 436–443.
- Fabian, I.D. & Sagoo, M.S. 2018. ‘Understanding retinoblastoma: epidemiology and genetics.’, *Community eye Heal.*, 31(101), p. 7.
- Faranoush, M. *et al.* 2014. ‘Consequences of delayed diagnosis in treatment of retinoblastoma.’, *Iran. J. Pediatr.*, 24(4), pp. 381–386.
- Foukakis, T. *et al.* 2018. ‘Immune gene expression and response to chemotherapy in advanced breast cancer.’, *Br. J. Cancer*, 118(4), pp. 480–488.
- Fujita, Y. *et al.* 2015. ‘The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer.’, *Mol. Ther.*, 23(4), pp. 717–727.
- Goddard, A.G., Kingston, J.E. & Hungerford, J.L. 1999. ‘Delay in diagnosis of retinoblastoma: risk factors and treatment outcome.’, *Br. J. Ophthalmol.*, 83(12), pp. 1320–1323.
- Grossniklaus, H.E. 2014. ‘Retinoblastoma. Fifty years of progress. The LXXI Edward Jackson Memorial Lecture.’, *Am. J. Ophthalmol. United States*, pp. 875–891.
- Guo, L. *et al.* 2019. ‘Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer.’, *J. Immunother.*, 42(6), pp. 215–220.
- Gupta, A. *et al.* 2020. ‘Therapeutic modulation of the CD47-SIRPα axis in the pediatric tumor microenvironment: working up an appetite’, *Cancer Drug Resist.*, pp. 550–562.

- He, X. & Xu, C. 2020. 'Immune checkpoint signaling and cancer immunotherapy', *Cell Res.*, 30(8), pp. 660–669.
- Hu, H. *et al.* 2018. 'Characterization, treatment and prognosis of retinoblastoma with central nervous system metastasis', *BMC Ophthalmol.*, 18(1), p. 107.
- Huang, C.-Y. *et al.* 2020. 'Regulation of CD47 expression in cancer cells.', *Transl. Oncol.*, 13(12), p. 100862.
- Huang, J. *et al.* 2022. 'Role of CD47 in tumor immunity: a potential target for combination therapy', *Sci. Rep.*, 12(1), pp. 1–11.
- Jabbari, N. *et al.* 2020. 'Modulation of Immune Checkpoints by Chemotherapy in Human Colorectal Liver Metastases.', *Cell reports. Med.*, 1(9), p. 100160.
- Jain, M. *et al.* 2019. 'Retinoblastoma in Asia.', *Eye (Lond.)*, 33(1), pp. 87–96.
- Jiang, Z. *et al.* 2021. 'Targeting CD47 for cancer immunotherapy.', *J. Hematol. Oncol.*, 14(1), p. 180.
- Kaliki, S. *et al.* 2013. 'High-risk retinoblastoma based on international classification of retinoblastoma: analysis of 519 enucleated eyes.', *Ophthalmology*, 120(5), pp. 997–1003.
- Kim, D. *et al.* 2012. 'Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells.', *Leukemia*, 26(12), pp. 2538–2545.
- Kodrat, H. & Gondhowiardjo, S. 2013. 'Radioterapi & Onkologi RADIOTERAPI PADA RETINOBLASTOMA', 4(1), pp. 17–23.
- Kovalchuk, A. *et al.* 2016. 'Sex-specific effects of cytotoxic chemotherapy agents cyclophosphamide and mitomycin C on gene expression, oxidative DNA damage, and epigenetic alterations in the prefrontal cortex and hippocampus - an aging connection.', *Aging (Albany. NY.)*, 8(4), pp. 697–711.
- Lee, T.K.-W. *et al.* 2014. 'Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma.', *Hepatology*, 60(1), pp. 179–191.
- Lehrman, E.K. *et al.* 2018. 'CD47 Protects Synapses from Excess Microglia-Mediated Pruning during Development', *Neuron*, 100(1), pp. 120-134.e6.
- Li, N. *et al.* 2022. 'Clinical Analysis of 16 Distant Metastatic Retinoblastoma Cases with Event-Free Survival.', *Cancer Manag. Res.*, 14, pp. 367–375.
- Li, Y. *et al.* 2017. 'Overexpression of CD47 predicts poor prognosis and promotes cancer cell invasion in high-grade serous ovarian carcinoma.', *Am. J. Transl. Res.*, 9(6), pp. 2901–2910.
- Lian, S. *et al.* 2019. 'Checkpoint CD47 function on tumor metastasis and immune therapy', *Onco. Targets. Ther.*, 12, pp. 9105–9114.
- Liu, J. *et al.* 2020. 'Single-cell RNA sequencing study of retinal immune regulators identified CD47 and CD59a expression in photoreceptors—Implications in subretinal immune regulation', *J. Neurosci. Res.*, 98(7), pp. 1498–1513.
- Lubis, B. 2001. 'Original article Clinical features of children with retinoblastoma in', *Dep. Child Heal. Med. Sch. Univ. North Sumatra/H Adam Malik Hosp. Medan, Indonesia*, (December 1999), pp. 234–236.
- Luo, X. *et al.* 2015. 'Clinical characteristics and prognosis of patients with retinoblastoma: 8-year follow-up.', *Turkish J. Med. Sci.*, 45(6), pp. 1256–1262.
- Madore, J. *et al.* 2015. 'PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials.', *Pigment Cell Melanoma Res.*, 28(3), pp. 245–253.
- Majeti, R. *et al.* 2009. 'CD47 is an adverse prognostic factor and therapeutic antibody

- target on human acute myeloid leukemia stem cells.’, *Cell*, 138(2), pp. 286–299.
- Manjandavida, F.P. *et al.* 2019. ‘Intra-arterial chemotherapy in retinoblastoma - A paradigm change.’, *Indian J. Ophthalmol.*, 67(6), pp. 740–754.
- Matozaki, T. *et al.* 2009. ‘Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway.’, *Trends Cell Biol.*, 19(2), pp. 72–80.
- Melamud, A., Palekar, R. & Singh, A. 2006. ‘Retinoblastoma.’, *Am. Fam. Physician*, 73(6), pp. 1039–1044.
- Modlich, O. *et al.* 2004. ‘Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease.’, *Clin. cancer Res. an Off. J. Am. Assoc. Cancer Res.*, 10(19), pp. 6418–6431.
- Murata, Y. *et al.* 2014. ‘The CD47-SIRPα signalling system: its physiological roles and therapeutic application.’, *J. Biochem.*, 155(6), pp. 335–344.
- Murata, Y. *et al.* 2018. ‘CD47-signal regulatory protein α signaling system and its application to cancer immunotherapy.’, *Cancer Sci.*, 109(8), pp. 2349–2357.
- Navo, E. *et al.* 2012. ‘Clinical presentation of retinoblastoma in a middle-income country.’, *J. Pediatr. Hematol. Oncol.*, 34(3), pp. e97–101.
- Ning, X. *et al.* 2021. ‘The prospect of immunotherapy combined with chemotherapy in patients with advanced non-small cell lung cancer: a narrative review.’, *Ann. Transl. Med.*, 9(22), p. 1703.
- Noman, M.Z. *et al.* 2014. ‘PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation.’, *J. Exp. Med.*, 211(5), pp. 781–790.
- Orozco-Morales, M. *et al.* 2021. ‘Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors.’, *J. Immunol. Res.*, 2021, p. 6632249.
- Padma, M. *et al.* 2020. ‘Epidemiology and clinical features of retinoblastoma: A tertiary care center’s experience in India.’, *South Asian J. cancer*, 9(1), pp. 56–58.
- Petralia, M.C. *et al.* 2019. ‘Characterization of the Pathophysiological Role of CD47 in Uveal Melanoma.’, *Molecules*, 24(13).
- Ramírez-Ortiz, M.A. *et al.* 2014. ‘Diagnostic delay and sociodemographic predictors of stage at diagnosis and mortality in unilateral and bilateral retinoblastoma.’, *Cancer Epidemiol. biomarkers Prev. a Publ. Am. Assoc. Cancer Res. cosponsored by Am. Soc. Prev. Oncol.*, 23(5), pp. 784–792.
- Rao, R. & Honavar, S.G. 2017. ‘Retinoblastoma.’, *Indian J. Pediatr.*, 84(12), pp. 937–944.
- Robert, C. *et al.* 2015. ‘Nivolumab in previously untreated melanoma without BRAF mutation.’, *N. Engl. J. Med.*, 372(4), pp. 320–330.
- Rodrigues, K.E.S., Latorre, M. do R.D.O. & de Camargo, B. 2004. ‘[Delayed diagnosis in retinoblastoma].’, *J. Pediatr. (Rio. J.)*, 80(6), pp. 511–516.
- Saiju, R. *et al.* 2013. ‘Retinoblastoma: geographic distribution and presentation at a tertiary eye care centre in Kathmandu, Nepal.’, *Nepal. J. Ophthalmol. a Biannu. peer-reviewed Acad. J. Nepal Ophthalmic Soc. NEPJOPH*, 5(2), pp. 169–176.
- Samanta, D. *et al.* 2018. ‘Chemotherapy induces enrichment of CD47<sup>+</sup>/CD73<sup>+</sup>/PDL1<sup>+</sup> immune evasive triple-negative breast cancer cells’, *Proc. Natl. Acad. Sci.*, 115(6), pp. E1239–E1248.
- Shields, C.L. & Shields, J.A. 2010. ‘Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy.’, *Curr. Opin. Ophthalmol.*, 21(3), pp. 203–212.

- Shifa, J.Z. & Gezmu, A.M. 2017. 'Presenting signs of retinoblastoma at a tertiary level teaching hospital in Ethiopia.', *Pan Afr. Med. J.*, 28, p. 66.
- Singh, G. & Daniels, A.B. 2016. 'Disparities in Retinoblastoma Presentation, Treatment, and Outcomes in Developed and Less-Developed Countries.', *Semin. Ophthalmol.*, 31(4), pp. 310–316.
- Singh, L. *et al.* 2015. 'Expression of CDC25A and CDC25B phosphatase proteins in human retinoblastoma and its correlation with clinicopathological parameters.', *Br. J. Ophthalmol.*, 99(4), pp. 457–463.
- Singh, L. *et al.* 2020. 'Clinical relevance of the comparative expression of immune checkpoint markers with the clinicopathological findings in patients with primary and chemoreduced retinoblastoma.', *Cancer Immunol. Immunother.*, 69(6), pp. 1087–1099.
- Soebagio, H. *et al.* 2013. 'Profile of Retinoblastoma in East Java, Indonesia', *Int. J. Epidemiol. Infect.*, 1(3), pp. 51–56.
- Soliman, S.E. *et al.* 2015. 'Socioeconomic and psychological impact of treatment for unilateral intraocular retinoblastoma.', *J. Fr. Ophthalmol.*, 38(6), pp. 550–558.
- Steinert, G. *et al.* 2014. 'Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer.', *Cancer Res.*, 74(6), pp. 1694–1704.
- Sugimura-Nagata, A. *et al.* 2021. 'Expression and Prognostic Significance of CD47-SIRPA Macrophage Checkpoint Molecules in Colorectal Cancer.', *Int. J. Mol. Sci.*, 22(5).
- Supartoto, A. *et al.* 2016. 'Exposure to exogenous female sex hormones is associated with increased risk of orbito-cranial meningioma in females: a case-control study', *Int J Ophthalmic Pathol* 5, 3(2).
- Supartoto, A. *et al.* 2020. 'The risk factor of metastatic status of retinoblastoma patient in Yogyakarta Tertiary Hospital', *J. the Med. Sci. (Berkala Ilmu Kedokteran)*, 52(01), pp. 9–16.
- Takimoto, C H *et al.* 2019. 'The Macrophage "Do not eat me" signal, CD47, is a clinically validated cancer immunotherapy target.', *Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.*, 30(3), pp. 486–489.
- Takimoto, C. H. *et al.* 2019. 'The Macrophage "Do not eat me" signal, CD47, is a clinically validated cancer immunotherapy target', *Ann. Oncol.*, 30(3), pp. 486–489.
- Thompson, S. *et al.* 2015. 'Retinoblastoma: Identifying the Diagnostic Signs for Early Treatment', *Int. J. Neurorehabilitation*, 2(2), pp. 1–11.
- Ting, S.C. *et al.* 2020. 'Bone metastasis of retinoblastoma five years after primary treatment.', *Am. J. Ophthalmol. case reports*, p. 100834.
- Tong, M. *et al.* 2016. 'Proteomic characterization of macro-, micro- and nano-extracellular vesicles derived from the same first trimester placenta: relevance for fetomaternal communication.', *Hum. Reprod.*, 31(4), pp. 687–699.
- Toor, S.M. *et al.* 2020. 'Immune checkpoints in the tumor microenvironment', *Semin. Cancer Biol.*, 65(May), pp. 1–12.
- Vasalaki, M. *et al.* 2017. 'Ocular oncology: advances in retinoblastoma, uveal melanoma and conjunctival melanoma.', *Br. Med. Bull.*, 121(1), pp. 107–119.
- Wang, Y. *et al.* 2013. 'Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis.', *Mol. Ther.*, 21(10), pp. 1919–1929.
- Xiao, W. *et al.* 2019. 'Associations among Socioeconomic Factors, Lag Time, and High-

- Risk Histopathologic Features in Eyes Primarily Enucleated for Retinoblastoma.’, *Curr. Eye Res.*, 44(10), pp. 1144–1149.
- Yanagita, T. *et al.* 2017. ‘Anti-SIRP $\alpha$  antibodies as a potential new tool for cancer immunotherapy’, *JCI Insight*.
- Yanoff, M. & Sassani, J. 2014. *Ocular Pathology E-Book: Expert Consult*. Elsevier Health Sciences.
- Yong, G.-Y. 2017. ‘Unilateral Trilateral Retinoblastoma with Spinal Metastases’, *Int. J. Ophthalmol. Clin. Res.*, 4(3), pp. 27–29.
- Zanaty, M. *et al.* 2014. ‘Update on Intra-Arterial Chemotherapy for Retinoblastoma’, *Sci. World J.* Edited by S.J. Monteith, 2014, p. 869604.
- Zhang, H. *et al.* 2015. ‘HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells.’, *Proc. Natl. Acad. Sci. U. S. A.*, 112(45), pp. E6215-23.
- Zhang, P. *et al.* 2016. ‘Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neoadjuvant chemotherapy.’, *Cancer Sci.*, 107(11), pp. 1563–1571.
- Zhao, H. *et al.* 2016. ‘CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer.’, *Sci. Rep.*, 6, p. 29719.
- El Zomor, H. *et al.* 2021. ‘Unilateral retinoblastoma; natural history and an age-based protocol in 248 patients’, *Eye*, 35(9), pp. 2564–2572.